VivoSeq
Oncology

Castration Resistant Prostatic Cancer

8

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Castration Resistant Prostatic Cancer is an early-stage landscape with 8 programs across 7 companies. The most active players are Johnson & Johnson, Glaxo Dba Glaxosmithkline, Eli Lilly. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3Merck & Co. logo

Merck & Co.

2 programs

PreclinicalA

Avyxa

1 program

PreclinicalDaiichi Sankyo logo

Daiichi Sankyo

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSAntibody–drug conjugate117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 70% of 10 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT03748641·765 enrolled
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT06863272·360 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)